Pathophysiology, treatment and experimental models of rheumatoid arthritis;Fisiopatología, tratamiento y modelos experimentales de artritis reumatoide

Revista Cubana de Farmacia

Volumn 45, Issue 2, 2011, Pages 297-308

  Puig, Miriam Noa ^a   Ferreiro, Rosa Más ^a   Castaño, Sarahí Mendoza ^a   Clara, Maikel Valle ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Pathophysiology; Polyarthritis; Rheumatoid arthritis; Rheumatoid factor; Treatment

Indexed keywords

COLLAGEN; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ADJUVANT THERAPY; ARTICLE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG INTOXICATION; EARLY DIAGNOSIS; EXPERIMENTAL MODEL; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; REHABILITATION CARE; RHEUMATOID ARTHRITIS; SYNOVITIS;

EID: 79959507047     PISSN: 00347515     EISSN: 15612988     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845-51.
2. Merkesdal S, Ruof J, Schoffski O. Indirect medical cost in early rheumatoid arthritis. Arthritis Rheum. 2001;44:528-34.
3. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21(1):27-42.
4. Lutteri L, Malaise M, Chapelle JP. Comparison of second and third-generation anticyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta. 2007;386(1-2):76-81.
5. Saraux A, Berthelot JM, Chales G. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum. 2001;44:2485-91.
6. Dao K, Cush J. Acute polyarthritis. Best Pract Res Clin Rheumatol. 2006;20(4):653-72.
7. Visser H, Cessie S, Vos K, Breedveld F, Hazes J. How to Diagnose Rheumatoid Arthritis Early. A Prediction Model for Persistent (Erosive) Arthritis. Arthritis Rheum. 2002;46(2):357-65.
8. Gormley G, Steele K, Gilliland D. Can rheumatologists agree on a diagnosis of inflammatory arthritis in an early synovitis clinic? Ann Rheum Dis. 2001;60:638-9.
9. Landewé R. Predictive Markers in Rapidly Progressing Rheumatoid Arthritis. J Rheumatol. 2007;34(Suppl 80):8-15.
10. Klareskog L, Stolt P, Lundberg K. New model for an etiology of rheumatoid arthritis: smoking may trigger HLADR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.
11. Rosenberg H. Enfermedades del mesénquima. Artritis reumatoide. En: Chuaqui B. Lecciones de Anatomía Patológica. Santiago de Chile: Pontificia Universidad Católica de Chile; 2009. [citado 30 Sept. 2010]. Disponible en: http://escuela.med.puc.cl/paginas/publicaciones/anatomiapatologica/11Enf_mesenquima/11artritis.html
12. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
13. Montesinos MC. Takedachi M, Thompson LF, Wilder TF, Fernández P, Cronstein BN. The anti-inflammatory mechanism of methotrexate depends on extracellularconversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56:1440-5.
14. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ. Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-82.
15. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005:52;3371-80.
16. Svensson B, Boonen, A.; Albertsson K, van der Heijde D, Keller, C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52:3360-70.
17. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X. Extended report. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov.;68(11):1708-14.
18. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007:56;3896-908.
19. El Bahri DM, Meddeb N, Sellami S. Rheumatoid arthritis: current status of therapy. Tunis Med. 2007 Jan;85(1):1-8.
20. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nature Rev Rheumatol. 2009;5:531-41.
21. Landewe RB, Boers M, Verhoeven AC. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347-56.
22. Korpela M, Laasonen L, Hannonen P. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81.
23. Kavanaugh A. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? Nat Clin Pract Rheumatol. 2006;2(7):346-7.
24. Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther. 2009 Dec.;9(12):1463-7.
25. Clair EW, Van der Heijde D, Smolen J, Maini R, Bathon J, Emery P, et al. Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis, A Randomized, Controlled Trial. Arthritis Rheum. 2004;50(11):3432-43.
26. Smolen J, Van der Heijde D, Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702-10.
27. Smolen J, Han C, Van der Heijde D, Emery P, Bathon J, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(3):716-22.
28. Mythilypriya R, Shanthi P, Sachdanandam P. Restorative and synergistic efficacy of Kalpaamruthaa, a modified Siddha preparation, on an altered antioxidant status in adjuvant induced arthritic rat model. Chem Biol Interact. 2007;168(3):193-202.
29. Mirshafiey A, Mohsenzadegan M. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iran J Allergy Asthma Immunol. 2008;7(4):195-202.
30. Bendele AM. Animal models of rheumatoid arthritis. J Musculoskel Neuron Interact. 2001;1(4):377-85.
31. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL. Utility of animal models foridentification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1505-15.
32. Asquith DL, Miller AM, McInnes IB. Animal models of rheumatoid arthritis. Eur J Immunol. 2009;39(8):2040-4.
33. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H. A crucial role for macrophages in the pathology of K/BxN serum-induced arthritis. Eur J Immunol. 2005;35:3064-73.
34. Mortiz F, Distler O, Ospelt C, Gay RE, Gay S. Technology insight: gene transfer and the design of novel treatment for rheumatoid arthritis. Nat Clin Pract Rheum. 2006;2:153-62.
35. Waksman BH. Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis. Scand J Immunol. 2002;56:12-34.
36. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56:1152-63.
37. Rasheed Z, Haqqi TM. Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev. 2008 Nov 1;4(4):246.
38. Bendele AM, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, Guy M. Animal models of arthritis:relevance to human disease. Toxicologic Pathol. 1999;27:134-42.
39. Willliams RO. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med. 2004;98:207-16.
40. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005;12:167-81.
41. Brand DD. Rodent models of rheumatoid arthritis. Comp Med. 2005;55:114-22.